Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression
Author:
Funder
NIH (RCMI)
Louisiana Cancer Research Consortium (LCRC)
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s13277-015-4518-4.pdf
Reference45 articles.
1. Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342:257–63.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
4. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.
5. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Low androgen/progesterone or high oestrogen/androgen receptors ratio in serous ovarian cancer predicts longer survival;Reproductive Biology;2024-09
2. Androgens in cervical cancer: Their role in epidemiology and biology;iScience;2024-07
3. The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer;Molecular Oncology;2024-03
4. Potential biomarkers and drug targets in glycoproteome of MCF-7 breast cancer cells based on proteomics and bioinformatics strategies Running title: Protein drug targets in MCF-7 cell line;2024-01-23
5. Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers;International Journal of Molecular Sciences;2022-07-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3